Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and

You are here:  Home >>  News >>  Market News >>  Breckenridge Announces Final Approval of its ANDA for Roflumilast Tablets

Breckenridge Announces Final Approval of its ANDA for Roflumilast Tablets

October 12, 2018 By americanpharmaceuticalreview

Breckenridge Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application for Roflumilast Tablets, 500mcg, generic for Daliresp Tablets by AstraZeneca Pharmaceutical. Breckenridge's Roflumilast Tablets product was developed by Ferrer International.

Roflumilast Tablets are a selective phosphodiesterase 4 inhibitor indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Daliresp generated annual sales of $211,000,000 during the year ended August 31, 2018, according to industry sales data.

AstraZeneca, Breckenridge, and Ferrer have entered into a confidential settlement agreement regarding the Hatch-Waxman litigation for Roflumilast. Breckenridge, as authorized by the settlement agreement, may sell or offer to sell Roflumilast at a later date. Further announcements will be made prior to product launch.

Editor's Note:

To apply for becoming a contributor of,

welcome to send your CV and sample works to us,


Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
live chat